CA2689260C - Combinaisons de vaccin contre une allergie aux chats - Google Patents

Combinaisons de vaccin contre une allergie aux chats Download PDF

Info

Publication number
CA2689260C
CA2689260C CA2689260A CA2689260A CA2689260C CA 2689260 C CA2689260 C CA 2689260C CA 2689260 A CA2689260 A CA 2689260A CA 2689260 A CA2689260 A CA 2689260A CA 2689260 C CA2689260 C CA 2689260C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
sequence
lfltgtpdeyveqvaqy
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2689260A
Other languages
English (en)
Other versions
CA2689260A1 (fr
Inventor
Roderick Peter Hafner
Mark Larche
Anthony Barrington Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38289716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2689260(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of CA2689260A1 publication Critical patent/CA2689260A1/fr
Application granted granted Critical
Publication of CA2689260C publication Critical patent/CA2689260C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte des compositions comprenant des peptides pour prévenir ou traiter une allergie aux chats, et en particulier sur des compositions optimales de peptides.
CA2689260A 2007-06-01 2008-05-30 Combinaisons de vaccin contre une allergie aux chats Active CA2689260C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0710529.9 2007-06-01
GBGB0710529.9A GB0710529D0 (en) 2007-06-01 2007-06-01 Vaccine
PCT/GB2008/001827 WO2008145998A1 (fr) 2007-06-01 2008-05-30 Combinaisons de vaccin contre une allergie aux chats

Publications (2)

Publication Number Publication Date
CA2689260A1 CA2689260A1 (fr) 2008-12-04
CA2689260C true CA2689260C (fr) 2023-02-28

Family

ID=38289716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2689260A Active CA2689260C (fr) 2007-06-01 2008-05-30 Combinaisons de vaccin contre une allergie aux chats

Country Status (17)

Country Link
US (3) US8551492B2 (fr)
EP (3) EP2079481B2 (fr)
JP (2) JP5366936B2 (fr)
CN (2) CN104027801A (fr)
AT (1) ATE481984T1 (fr)
AU (1) AU2008256524B2 (fr)
CA (1) CA2689260C (fr)
CY (1) CY1110980T1 (fr)
DE (1) DE602008002693D1 (fr)
DK (1) DK2079481T4 (fr)
ES (2) ES2573700T3 (fr)
GB (1) GB0710529D0 (fr)
HR (1) HRP20100644T1 (fr)
PL (1) PL2079481T3 (fr)
PT (1) PT2079481E (fr)
SI (1) SI2079481T1 (fr)
WO (2) WO2008146003A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
EP2331124A1 (fr) 2008-08-15 2011-06-15 Circassia Limited Peptide de l antigène des cellules t d allergène destiné à stimuler la production d il-10
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
HRP20150317T1 (hr) 2009-02-05 2015-04-24 Circassia Limited Peptidi trave za cjepivo
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
WO2015042664A1 (fr) 2013-09-25 2015-04-02 Monash University Nouvelle composition immunothérapeutique et utilisations associées
GB2523399B (en) * 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
GB2559499A (en) * 2014-02-25 2018-08-08 Orban Tihamer Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
JP2018527395A (ja) * 2015-09-30 2018-09-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 改良モジュール型抗原移送分子及び動物におけるその使用
US20190070287A1 (en) * 2016-02-12 2019-03-07 Virtici, Llc Tolerance therapeutic for treating polypeptide induced immune activation
RS67826B1 (sr) 2016-12-22 2026-03-31 Regeneron Pharma Postupak za lečenje alergije sa monoklonskim antitelima specifičnim za alergen
WO2022180102A1 (fr) * 2021-02-23 2022-09-01 Specialites Pet Food Nouvelles protéines de liaison odorantes canines
CN117627400B (zh) * 2024-01-26 2024-04-12 辽宁美耐金属建筑系统有限公司 一种金属屋面屋脊防坠落系统及防坠方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (fr) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycérol comme protecteur du groupe thiol dans des produits lyophilisés
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
ES2174822T3 (es) 1989-11-03 2002-11-16 Immulogic Pharma Corp Una proteina felina reactiva con celulas t humanas (trfp) aislada de polvo domestico y usos para la misma.
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
DE69233772D1 (de) 1991-10-16 2009-11-12 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
WO1994024281A1 (fr) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation Epitopes de lymphocytes t des principaux allergenes de dermatophagoides (acariens detriticoles)
CA2117779A1 (fr) 1992-04-09 1993-10-28 Mei-Chang Kuo Determinants antigeniques du lymphocyte t des principaux allergenes d'ambroise artemisifolia
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
US5939283A (en) * 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
CA2157596A1 (fr) 1993-03-12 1994-09-29 Irwin J. Griffith Epitopes de cellules t de l'allergene du pollen de ray-grass
EP0705108A4 (fr) 1993-06-02 1997-08-06 Tvw Telethon Inst Child Health Peptides caches permettant d'induire une tolerance immunologique
JPH09504167A (ja) 1993-08-13 1997-04-28 イミュロジック ファーマスーティカル コーポレイション ドクムギ花粉アレルゲンのｔ細胞エピトープ
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
DK0755407T3 (da) 1994-04-14 2007-08-06 Merck Patent Gmbh Farmaceutisk peptidformuleringer til behandling af stövmideallergi
US5968526A (en) * 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
EP0783322A1 (fr) 1994-09-02 1997-07-16 Immunologic Pharmaceutical Corporation Compositions peptidiques pouvant reguler a la baisse une reponse immunitaire specifique a un antigene
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
WO1999032135A1 (fr) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Formulations du facteur-2 de croissance des keratinocytes
GB2348808B (en) * 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
CN102764425B (zh) 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
EP1450847B1 (fr) 2001-11-13 2010-09-29 Genentech, Inc. Compositions à base de APO2 ligand/TRAIL et leur utilisation
EP1453539B1 (fr) * 2001-12-05 2008-11-19 Circassia Limited Procedes et systemes immunotherapeutiques
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
WO2003093299A2 (fr) 2002-05-06 2003-11-13 Thomas Jefferson University Peptides lies a l'insuline ayant des effets sur la sante cerebrale
US20040071718A1 (en) * 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
JP2007524583A (ja) 2003-03-07 2007-08-30 ロンドン・ヘルス・サイエンシズ・センター・リサーチ・インコーポレーテッド 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
PT1636261E (pt) 2003-06-26 2007-11-08 Merck Patent Gmbh Proteínas trombopoietina com propriedades melhoradas
GB0315754D0 (en) 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
EP1685160A1 (fr) 2003-11-10 2006-08-02 Arriva-Prometic Inc. Preparation seche de alpha 1-antitrypsine humaine obtenue par recombinaison
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
CN1913917B (zh) 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
WO2006075253A2 (fr) † 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides destines a desensibiliser des sujets allergiques au poil de chien ou aux squames, et compositions contenant ces peptides
KR20070100832A (ko) 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
CA2630840A1 (fr) * 2005-11-23 2007-05-31 Universitaet Zuerich Traitement d'une allergie par administration epicutanee d'un allergene
CN1840708A (zh) * 2006-01-23 2006-10-04 南开大学 用于治疗免疫耐受相关疾病的基因的筛选和鉴定方法
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
GB0701048D0 (en) 2007-01-18 2007-02-28 Univ Aberdeen A composition
EP1958645A1 (fr) 2007-02-13 2008-08-20 Biomay AG Peptides dérivés du allergène majeur de l'ambrosie (Ambrosia artemisiifolia) et leur utilisation
WO2008115428A2 (fr) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Procédé de fabrication modulable de cystéine endoprotéase b, isoforme 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation

Also Published As

Publication number Publication date
DK2079481T4 (en) 2016-09-19
EP2079481B2 (fr) 2016-06-15
EP2380591A2 (fr) 2011-10-26
EP2079481A1 (fr) 2009-07-22
US20140050750A1 (en) 2014-02-20
EP2428222B1 (fr) 2016-03-23
CA2689260A1 (fr) 2008-12-04
WO2008146003A1 (fr) 2008-12-04
EP2380591A3 (fr) 2012-05-09
WO2008145998A1 (fr) 2008-12-04
ES2353360T3 (es) 2011-03-01
DE602008002693D1 (de) 2010-11-04
JP2013256507A (ja) 2013-12-26
US20100239599A1 (en) 2010-09-23
ES2573700T3 (es) 2016-06-09
GB0710529D0 (en) 2007-07-11
DK2079481T3 (da) 2011-01-17
JP5857002B2 (ja) 2016-02-10
ES2353360T5 (es) 2016-08-19
ATE481984T1 (de) 2010-10-15
US9168295B2 (en) 2015-10-27
PT2079481E (pt) 2010-12-23
CY1110980T1 (el) 2015-06-11
EP2428222A3 (fr) 2012-05-09
AU2008256524A1 (en) 2008-12-04
EP2428222A2 (fr) 2012-03-14
SI2079481T1 (sl) 2011-02-28
HRP20100644T1 (hr) 2011-01-31
US20160120965A1 (en) 2016-05-05
JP2010529836A (ja) 2010-09-02
CN104027801A (zh) 2014-09-10
US8551492B2 (en) 2013-10-08
HK1132935A1 (en) 2010-03-12
EP2079481B1 (fr) 2010-09-22
PL2079481T3 (pl) 2011-03-31
CN101808660A (zh) 2010-08-18
JP5366936B2 (ja) 2013-12-11
CN101808660B (zh) 2014-04-02
AU2008256524B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
CA2689260C (fr) Combinaisons de vaccin contre une allergie aux chats
EP2083856B1 (fr) Peptides pour la desensibilisation contre les allergenes
JP5788319B2 (ja) ブタクサアレルギーの治療用のＡｍｂａ１ペプチド
AU2013202871B2 (en) Vaccine peptide combinations against cat allergy
HK1164713A (en) Vaccine peptide combinations against cat allergy
HK1163523A (en) Vaccine peptide combinations against cat allergy
HK1132935B (en) Vaccine peptide combinations against cat allergy
HK1197363A (en) Vaccine peptide combinations against cat allergy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130506

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260323

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407